Diabetes research is coming to Stouffville! This fall, Stouffville Medical Centre will host its first clinical trial for type 2 diabetes, for people who have been diagnosed within the past 4 years. JoinAStudy.ca Principal Investigator Dr. Nima Mirtorabi and the medical team in Stouffville are excited to be contributors to the next wave of diabetes
JoinAStudy.ca Investigators Dr. Peter Dzongowski, Dr. Michael Jones and Dr. Sean Peterson were all recently involved in GSK trial AReSVi 006, evaluating a vaccine candidate for Respiratory Syncytial Virus (RSV). Recruitment was highly successful for all three investigators, whose work has helped lead to the first RSV vaccine candidate to show statistically significant and clinically
JoinAStudy.ca Investigator Dr. Anil Gupta was recently asked to assist in the presentation of strategies for preventing COVID progression and transmission in the outpatient setting, including the latest therapeutic developments. This effort was supported by an educational grant from Merck Sharp & Dohme Corp. The presentation linked below will define the sub-populations that are most
Canada has approved the first oral COVID-19 treatment that can be taken at home. The drug, an antiviral developed by Pfizer, was found to reduce risk of hospitalization and death by 89 percent in clinical trials. At the moment, there is a “limited global supply” of the drug, thus Canadian health officials have prioritized the
Earlier this year, we reported on the positive findings of a Covid-19 treatment study, conducted by lead study author and JoinAStudy Investigator Dr. Anil Gupta. We are now proud to highlight that as of November 18, 2021 this research has been published in the prestigious New England Journal of Medicine. It is among the most reputable peer-reviewed medical
UPDATE 28/10/2021 Dr. Gupta’s work as lead researcher on this study has been published in The New England Journal of Medicine, in an article titled Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. You can find a link to the article on The Journal‘s website, here: https://www.nejm.org/doi/full/10.1056/NEJMoa2107934?query=featured_home UPDATE 30/8/2021 Dr. Gupta has given two
A round of applause for our research site physicians Dr Sam Henein and Dr Michael O’Mahony for their participation in the Amarin REDUCE-IT hypertriglyceridemia study!
The Food and Drug Administration (FDA) of the United States of America has recently issued a statement, updating Research Sites, Investigators, and IRBs on how best to deal with the ongoing challenges posed by COVID-19. These guidelines will help ensure the safety of trial participants, compliance with good clinical practice (GCP), and minimizing risks to
Approximately 550,000 Canadians suffer from the neurodegenerative disease known as Alzheimer’s Disease, which is also the cause of 60% to 70% of cases of dementia. This disease is associated with symptoms such as memory loss, difficulty performing simple tasks, disorientation of time and space, and even sudden changes in mood or personality. It is a
Last summer, we reported that Health Canada and the FDA were beginning a series of meetings to discuss how Canada and the U.S. could work together to make their drug approval processes more efficient. At that time, they announced the formation of a council (it’s called the Canada-US Regulatory Cooperation Council, or RCC) to look
